LATEST FROM IPOX^®

News

News and updates from IPOX^®, including media mentions, interviews, research and press releases.

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Odyssey Therapeutics’ Nasdaq Debut

Reuters reported that Odyssey Therapeutics reached a nearly $900 million valuation after shares rose in its Nasdaq debut. IPOX^® Research Associate Lukas Muehlbauer said the trend suggests the “biotech IPO window is open again after a lackluster 2025.” He also noted, “In a biotech market where M&A remains an important exit route for recently listed companies, investors may view Glick’s history as adding to Odyssey’s appeal,” citing founder Dr. Gary D. Glick’s biotech track record.

May 8, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer Comments on Lime’s Nasdaq IPO Filing

Reuters reports Lime filed for a U.S. IPO, with IPOX^® Research Associate Lukas Muehlbauer noting, “Lime’s filing reflects both a better IPO market and a stronger company profile than in the previous years.” He added, “While the underlying picture has improved meaningfully, the main caveat is that the company remains loss-making and investors will look closely at whether they can turn strong revenue numbers into more consistent profitability.” Lime plans to list on Nasdaq under “LIME.”

May 8, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® CEO Josef Schuster Comments on Blackstone Data Center Vehicle’s U.S. IPO

Reuters reports Blackstone Digital Infrastructure Trust is aiming to raise slightly over $1.7 billion in a U.S. IPO to acquire newly built data centers amid strong demand for AI-linked infrastructure. IPOX^® CEO Josef Schuster is quoted on the strength of the U.S. IPO market, noting that gains in AI- and energy-related deal flow have supported sentiment and demand for new listings. The Blackstone vehicle plans to list on the NYSE under the symbol “BXDC.”

May 4, 2026Josef Schuster

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Cerebras’ IPO and AI Chip Demand

Reuters reports Cerebras Systems is targeting a valuation of up to $26.62 billion in its U.S. IPO, amid strong investor demand for AI infrastructure and advanced chips. IPOX^® Research Associate Lukas Muehlbauer is quoted on Cerebras’ competitive positioning against Nvidia, its role as a signal deal for high-growth AI infrastructure listings, and the potential race to complete offerings before a major SpaceX IPO draws investor attention and capital in the Reuters article published May 4, 2026.

May 4, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Pershing Square USA’s NYSE Debut

Reuters reported that Bill Ackman’s Pershing Square and Pershing Square USA are set to list on the NYSE after Pershing Square USA raised $5 billion in its IPO. The debut marks Ackman’s renewed effort to bring a flagship U.S.-listed fund to market and tests investor appetite for closed-end funds. IPOX^® Research Associate Lukas Muehlbauer was quoted on the offering’s structure, noting that shares of the managing company may have helped support investor demand beyond the fund alone in the listing.

April 29, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Rare Earths Americas’ U.S. IPO Roadshow

Reuters reported that Rare Earths Americas launched its U.S. IPO roadshow, targeting a valuation of up to $368.4 million amid rising investor interest in critical minerals. The company plans to raise up to $52.8 million and list on NYSE American under “REA”. IPOX^® Associate Lukas Muehlbauer was quoted, noting the company’s role in supply-chain diversification and the potential M&A appeal of newly public rare earth companies in a strategically important sector as global demand continues to accelerate sharply worldwide.

April 28, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® CEO Josef Schuster Discusses Lincoln International's IPO Filing and the "Golden Age" of U.S. Listings

Lincoln International has filed for a rare U.S. initial public offering, joining the ranks of publicly traded boutique investment banks like Moelis and Houlihan Lokey. The Chicago-based firm, which reported $214.1 million in net income on $783.8 million in revenue for 2025, is capitalizing on a rebounding global dealmaking environment. IPOX^® CEO Josef Schuster highlighted the asset class's resilience against recent geopolitical volatility, stating a "golden age for U.S. IPOs has arrived" amidst strong demand for U.S.-domiciled specialty deals.

April 25, 2026Josef Schuster

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer Comments on Liftoff's U.S. IPO Filing

Blackstone-backed mobile app marketing firm Liftoff has officially filed for a U.S. IPO on the Nasdaq under the ticker "LFTO." The company previously paused its listing plans amid market volatility but is now capitalizing on a broader rebound in technology stocks and easing geopolitical tensions. IPOX^® Research Associate Lukas Muehlbauer provided expert commentary to Reuters, noting that Liftoff is strategically utilizing this reopening IPO window as investors view the recovering software space as increasingly attractive for new equity listings.

April 18, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Kailera Therapeutics' Nasdaq Debut

IPOX^® Research Associate Lukas Muehlbauer was featured in a recent Reuters article discussing Kailera Therapeutics' $625 million IPO. As shares surged 62.5%, the debut signals a potential biotech IPO market turnaround. Muehlbauer highlighted the strong demand for GLP-1 companies, stating, "Obesity remains one of the few areas in biotech with clear investor appetite." He noted near-term trading relies heavily on broader obesity-drug space fundamentals.

April 17, 2026Lukas Muehlbauer

News

Stay ahead of the next listing.